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Introduction: Abnormal oxidative stress has been described in systemic sclerosis (SSc) and previous works from
our laboratory demonstrated an increased generation of reactive oxygen species (ROS) by SSc fibroblasts and
monocytes. This study investigated the ability of SSc T lymphocytes to produce ROS, the molecular pathway
involved, and the biological effects of ROS on SSc phenotype.
Methods: Peripheral blood T lymphocytes were isolated from serum of healthy controls or SSc patients by negative
selection with magnetic beads and activated either with PMA or with magnetic beads coated with anti-CD3
and anti-CD28 antibodies. Intracellular ROS generation was measured using a DCFH-DA assay in a plate reader
fluorimeter or by FACS analysis. CD69 expression and cytokine production were analyzed by FACS analysis. Protein
expression was studied using immunoblotting techniques and mRNA levels were quantified by real-time PCR. Cell
proliferation was carried out using a BrdU incorporation assay.
Results: Peripheral blood T lymphocytes from SSc patients showed an increased ROS production compared to T
cells from healthy subjects. Since NADPH oxidase complex is involved in oxidative stress in SSc and we found high
levels of gp91phox in SSc T cells, SSc T cells were incubated with chemical inhibititors or specific siRNAs against
gp91phox. Inhibition of NADPH oxidase partially reverted CD69 activation and proliferation rate increase, and
significantly influenced cytokine production and ERK1/2 activation.
Conclusions: SSc T lymphocityes are characterized by high levels of ROS, generated by NADPH oxidase via ERK1/2
phosphorylation, that are essential for cell activation, proliferation, and cytokine production. These data confirm
lymphocytes as key cellular players in the pathogenesis of systemic sclerosis and suggest a crucial link between
ROS and T cell activation.Introduction
Systemic sclerosis or scleroderma (SSc) is a connective
tissue disease of unknown origin characterized by exces-
sive deposition of collagen and other extracellular matrix
components in skin and visceral organs, severe alter-
ations in the microvasculature, and humoral and cellular
immunologic abnormalities [1,2].
Although the pathogenesis of SSc is unclear, several
features suggest that activation of immune cells plays a
central role in the development of the disease [3-6].* Correspondence: a.gabrielli@univpm.it
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stated.Upregulation of collagen synthesis in fibroblasts adja-
cent to infiltrating T cells suggests that T cells can trig-
ger fibroblast activation both by direct contact and by
paracrine action through the production of soluble me-
diators [7-10]. On the other hand, chemokines secreted
by activated fibroblasts can induce chemotaxis of inflam-
matory cells, contributing to the amplification of the
pathogenetic process [11].
Reactive oxygen species (ROS) have long been consid-
ered deleterious byproducts of mitochondrial and endo-
somal metabolic activities. Over the past few years,
numerous studies have demonstrated that T lymphocytes
also produce ROS, upon T cell receptor (TCR) stimulation
[12] or after treatment with lectins (concanavalin AThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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gens (phorbol myristate acetate (PMA) or superantigens)
[13,16,17]. ROS production in T cells is involved in the
regulation of T helper (Th)1/Th2 balance, in T cell matur-
ation, proliferation and survival through the modulation
of signal transduction [18]. The available data on the
mechanism used by T cells to produce ROS are limited,
although lipid metabolism, mitochondria and NADPH
oxidase seem to be the most important sources [19,20].
Following Murrell’s hypothesis [21,22], several reports
have provided indirect [23,24] and direct evidence [25]
of abnormal ROS generation in SSc. We have previously
demonstrated that monocytes and fibroblasts from SSc
patients represent a source of free radical species [25,26].
In this study, we present data demonstrating that un-
stimulated T lymphocytes from SSc patients are able to
produce ROS, and we show the molecular pathways in-
volved in ROS generation.
Methods
Human subjects
Thirty-four nonsmoking SSc patients (six men and twenty-
eight women) with a median age of 57 years (range 27 to
84) were studied. The clinical features of SSc population
are presented in Table S1 in Additional file 1. Diagnosis
was made following the American College of Rheumatol-
ogy preliminary criteria for the classification of SSc [27],
and the patients were classified into the diffuse SSc and
limited SSc subset according to LeRoy et al. [28]. The
study was approved by the Institutional Ethics Committee
of Università Politecnica delle Marche, Ancona, Italy.
An informed written consent was obtained from all pa-
tients. At the time of the investigation the patients, who
had never been on immunosuppressive therapy, had not
received any treatment for the previous six weeks.
Seventeen age-, sex- and race-matched, normal, non-
smoking, healthy volunteers were also evaluated and
constituted the control population.
Isolation of lymphocytes
Mononuclear cell suspensions were prepared from
heparin-collected peripheral blood (PB) of patients and
healthy controls by Ficoll-Hypaque density gradient
centrifugation. Peripheral blood lymphocytes (PBL) were
separated after removal of monocytes by adherence. In se-
lected experiments residual monocytes and B lymphocytes
were further depleted by incubating with CD14 and
CD19 magnetic microbeads according to the manufac-
turer’s instructions (Miltenyi Biotec, Bergisch Gladbach,
Germany). Otherwise, PB T cells were purified using a
negative isolation procedure (T Cell Negative Isolation
kit; Dynal; Invitrogen, Carlsbad, CA, USA), which re-
sulted in a 95% CD3+ cell population, as assessed by
FACS analysis after staining with a peridinin chlorophylprotein (PerCP)-conjugated anti-CD3 monoclonal anti-
body (Becton Dickinson, Franklin Lakes, NJ, USA). T
cells were then resuspended at 1 × 106 cells/ml in RPMI
1640 medium, supplemented with 10% fetal calf serum
(FCS), 2 mM L-glutamine, 100 U/ml penicillin/strepto-
mycin, at 37°C in a humidified atmosphere with 5% CO2.ROS determination
Relative changes in intracellular ROS were monitored
using the fluorescent probe dichloro-dihydro-fluorescein
diacetate (DCFH-DA) (Life Technologies, Carlsbad, CA,
USA). Cells were incubated with different inhibitors,
PD98059 (50 μM, 2 hours) (Calbiochem, Billerica, MA,
USA), diphenyleneiodonium (DPI, 20 μM, 1 hour) (Cal-
biochem), N-acetyl-cysteine (NAC 10 mM, 1 hour)
(Sigma-Aldrich, St Louis, MO, USA), or cytokines,
interleukin (IL)-1 (10 ng/ml), IL-4 (15 ng/ml), IL-6
(5 ng/ml), IL-13 (50 ng/ml), interferon alpha (IFNα)
(0.5 ng/ml), tumor necrosis factor alpha (TNFα) (1 ng/
ml), transforming growth factor beta (TGFβ) (1 ng/ml),
and platelet-derived growth factor beta (PDGF-BB)
(15 ng/ml) for 15 minutes. Cells were then stained with
20 μM DCFH-DA for 20 minutes and analyzed in a
plate reader fluorimeter (Wallac, Becton Dickinson).
ROS production was also detected by FACS analysis. In
brief, cells were treated and stained with 2 μM DCFH-
DA for 30 minutes and fluorescence was measured
using an argon ion laser at 488 nm excitation and 510
to 540 nm emission on a FACscan flow cytometer
(Becton Dickinson).Western blots
Total cell lysates were separated by sodium dodecyl sulfate
(SDS)-polyacrylamide gels as already described [26]. Anti-
bodies against ERK2, pERK1/2, Ha-Ras, and gp91phox
(Santa Cruz Biotechnology, Dallas, TX, USA) were used.Immunofluorescence
For double staining, PBL were incubated simultaneously
with 2 μM DCFH-DA and PerCP-conjugated anti-CD3
antibody (Becton Dickinson) for 20 minutes and analyzed
on a FACscan flow cytometer.Small interference RNA transfection
T lymphocytes were transfected with 100 nM small inter-
fering RNA (siRNA) specific for gp91phox (Dharmachon,
Lafayette, CO, USA) or control siRNA using Lipofecta-
mine™ 2000 reagent, following the manufacturer’s in-
structions (Life Technology). After 4 hours, 10% FCS
and 20 U/ml IL-2 were added to the culture medium.
Gene silencing and ROS production were monitored
72 hours after transfection.
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Total RNA was isolated with Pure Link RNA Minikit
(Life Technologies) and reverse transcribed using IScript
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules,
CA, USA) according to the manufacturer’s instructions.
Gene expression was quantified by SYBR Green real-time
PCR in a iCycler iQ™ real-time PCR Detection System
(Bio-Rad Laboratories). Specific primer pairs for each gene
were designed with the Universal ProbeLibrary Assay
Design Center by Roche Applied Science (Penzberg,
Germany) and were as follows: gp91phox 5′-TCACT
TCCTCCACCAAAACC-3′ (forward), 5′GGGAT-TGG
GCATTCCTTTAT3′ (reverse); GAPDH 5′-TGCACCA
CCAACTGCTTAGC-3′ (forward), 5′-TGGGATTTCC
ATTGATGACAAGC-3′ (reverse). The relative expres-
sion was calculated using the 2_ΔΔCt formula.
Proliferation assay
T cells were treated with DPI (10 μM) and PD98059
(20 μM) for 48 hours and then pulsed with bromodeox-
yuridine (BrdU) for 6 hours. Proliferation was measured
with a colorimetric immunoassay (Roche Diagnostics,
Mannheim, Germany).
Viability assay
After specific treatments, cells were incubated with
20 mg/ml 7-aminoactinomycin D (7-AAD) (Sigma-Aldrich)
for 20 minutes at 4°C in the dark and then acquired on
a FACScan flow cytometer.
Cytokine determination
For intracellular staining assay, isolated T cells were
treated with 20 μM DPI for 1 hour and then stimu-
lated with 100 ng/ml PMA and 20 U/ml IL-2 for
4 hours. After 2-hour incubation with Brefeldin A
(Sigma-Aldrich), cells were permeabilized with Cyto
Fix/Perm (Becton Dickinson). Intracellular staining was
performed with PerCP-conjugated anti-IL-4 antibody
(BioLegend, San Diego, CA, USA) or fluorescein iso-
thiocyanate (FITC)-conjugated anti-interferon γ (IFNγ)
antibody (Becton Dickinson). Cells were then analyzed
by FACS analysis.
Statistical analysis
Data are expressed as means ± standard deviation (SD).
Mean values were compared using Student’s paired and
unpaired t test. P values less than 0.05 were considered
significant.
Results
Spontaneous ROS production by peripheral blood
lymphocytes from SSc patients
We previously demonstrated that unstimulated mono-
cytes isolated from SSc patients released large amount ofreactive oxygen species (ROS) [25]. These data led us to
investigate whether other blood cell types were involved
in the oxidative burst that characterizes SSc. Peripheral
blood lymphocytes (PBL) were obtained from 17 healthy in-
dividuals and 34 SSc patients (Table S1 in Additional file 1)
and analyzed for ROS production. PBL from SSc patients
produced a significantly larger amount of ROS compared to
healthy controls as measured in a plate reader fluorimeter
(150 ± 45 and 100 ± 20 respectively, Figure 1A) and by
FACS analysis (100 and 46.2 ± 8 respectively, Figure 1B)
(P <0.05). We then analyzed the relationship between the
amount of ROS generated by PBL and the clinical features
of SSc patients. No difference was detected when all patients
were divided into the limited or the diffuse subset (17
limited SSc patients 132.8 ± 56 vs. 17 diffuse SSc pa-
tients 163.3 ± 48, P = 0.066), or into early (less than
5 years) or late (6 years or more) disease (17 early SSc
patients 157.37 vs. 17 late SSc patients 161.25,
P = 0.45). In order to identify the PB cell subpopulation
responsible for the increased ROS production in SSc
samples, we purified cell populations depleted of CD14
(CD14-) and CD19 (CD19-) fractions by magnetic
beads. Since no difference in ROS generation between
PBL and the purified cell populations was observed, we
could assume that neither CD14+ nor CD19+ cells
were responsible for the oxidative burst in SSc samples
(Figure 1C and D respectively). To test whether ROS
generation by PBL was due to T cells, we performed a
negative selection procedure specific for T cell isolation
in 12 controls and in 23 SSc samples and ROS produc-
tion was analyzed. Figure 2A shows that T cells from
SSc patients, even in absence of deliberate stimulation,
produced significantly larger amount of ROS compared
to T cells from healthy controls (186 ± 17 and 100 ± 15
respectively, P <0.05). Data were confirmed by FACS
analysis (Figure 2A, lower panel). No difference was de-
tected when all patients were divided into the limited
or the diffuse subset (P = 0.13). The simultaneous stain-
ing of SSc PBL with DCFH-DA and anti-CD3 PerCP-
conjugated antibody confirmed the implication of T cell
population in ROS production. To understand which
subpopulation of T cells was implicated in ROS produc-
tion, we stained SSc PBL with DCFH-DA and PE-
conjugated anti-CD4 (Figure S1A in Additional file 2)
or anti-CD8 antibody (Figure S1B in Additional file 2).
We observed that both CD4+ and CD8+ lymphocytes
were involved in ROS generation. To further validate
the involvement of CD3+ T cells in ROS generation,
CD3+ T cells from SSc patients were treated with
10 mM N-acetylcysteine (NAC), a ROS scavenging
agent, and a significant reduction in free radical pro-
duction was observed (100 ± 10 and 60 ± 5 respectively,
P <0.05) (Figure 2C). These results were confirmed by
FACS analysis (Figure 2D).
Figure 1 ROS production by PBL from SSc patients and healthy controls. (A) PBL from 17 healthy controls (white bar) and 34 SSc patients
(black bar), isolated from peripheral blood were stained with 20 μM DCFH-DA for 20 minutes, and fluorescence was measured in a plate reader
fluorimeter. Each patient and control was tested three times and the mean value used to calculate the mean of each group. Data are means ±
standard deviation (SD). *P <0.05 compared to normal PBL. (B) ROS production by PBL from one healthy control (black line) and one SSc patient
(grey line) was analyzed by FACS analysis. A representative histogram of three independent experiments is shown. (C and D) SSc CD14- (C) and
SSc CD19- cells (D) were purified from PBL using CD14 and CD19 microbeads. The total fractions of cells (PBL, white bars) and the collected
depleted fractions (black bars) were stained with 20 μM DCFH-DA for 20 minutes, and fluorescence was measured on a plate reader fluorimeter.
Data are means ± SD of three independent experiments with cells from three distinct subjects. DCFH-DA, 2′, 7′-dichlorodihydrofluorescin
diacetate; PBL, peripheral blood lymphocytes; ROS, reactive oxygen species; SSc, systemic sclerosis.
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T lymphocytes
Since human T cells express a functional gp91phox (NOX2)
[29], we were interested to investigate whether this enzymatic
complex was also implicated in ROS production in SSc T lym-
phocytes. SSc T cells expressed higher amount of gp91phox at
protein (Figure 3A) and transcriptional levels (Figure 3B)
compared to healthy controls. Treatment of SSc T cells with
DPI, a specific inhibitor of flavonoid-containing enzymes
such as NADPH oxidase, determined a 50% reduction in
ROS production (P <0.05), confirming the important role
of NADPH oxidase in ROS generation (Figure 3C). More-
over, transfection of SSc T cells with siRNA specific for
gp91phox led to a significant decrease of ROS generation
compared to cells transfected with a control siRNA (100
± 15 and 63 ± 5 respectively, P <0.05) (Figure 3D).
The implication of extracellular signal-regulated kinase
(ERK)1/2 signaling in ROS production has been assessed
in different cell types, including T lymphocytes [18], and
in a previous work, we described an intracellular loop that
involves Ha-Ras, ERK1/2, and ROS, leading to increasedcollagen gene expression in SSc fibroblasts [30]. To
evaluate the involvement of ERK1/2 signaling in ROS
production in SSc T cells, we treated T lymphocytes
from SSc patients with PD98059, an ERK1/2 inhibitor.
As shown in Figure 4A, PD98059 significantly reduced
DCFH-DA fluorescence intensity compared to untreated
cells (100 ± 15 and 75 ± 8, P <0.05), confirming ERK1/2
implication in ROS production in SSc T cells.
It has been reported that ROS produced by the NADPH
oxidase system could modulate MEK/ERK pathway activa-
tion [12]. In order to validate this hypothesis, we examined
the activation levels of ERK1/2 in SSc T lymphocytes in the
presence or absence of NAC or DPI. Figure 4B shows that
in basal conditions, SSc samples expressed higher levels of
pERK1/2 compared to healthy controls. Inhibition of
NADPH oxidase with DPI or treatment with NAC in SSc T
cells determined a reduction of activated ERK1/2 levels,
demonstrating an important role for ROS in the up-
stream activation signaling of MEK/ERK in SSc T cells.
We then compared Ha-Ras levels in SSc and normal T
lymphocytes and the modulation of Ha-Ras by ROS
Figure 2 ROS production by T cells from SSc patients and healthy controls. (A) T lymphocytes from 12 healthy controls (white bar) and 23
SSc patients (black bar) purified using a negative selection procedure were stained with 20 μM DCFH-DA, and the fluorescence was quantified in a
plate reader fluorimeter (upper panel). Each patient and control was tested three times and the mean value used to calculate the mean of each group.
Data are means ± standard deviation (SD). *P <0.05 compared to normal T cells. Representative histogram of ROS production in T cells from one
healthy control (black line) and one SSc patient (grey line) analyzed by FACS analysis is shown in the lower panel. (B) ROS production in total (grey line)
and in CD3+ PBL (black line) from one SSc patient simultaneously stained with 2 μM DCFH-DA and monoclonal PerCP-conjugated anti-CD3 antibody
for 20 minutes was analyzed by FACS analysis. Histogram is representative of three independent experiments. (C) CD3+ T lymphocytes isolated from
10 SSc patients and treated with NAC (10 mM, 1 hour) were stained with 20 μM DCFH-DA for 20 minutes, and the fluorescence was measured in a
plate reader fluorimeter. Each treatment was tested three times and the mean value used to calculate the mean of each group. Data are means ± SD.
*P <0.05 compared to untreated T cells (control). (D) Untreated (control, grey line) or treated with NAC CD3+ T cells (black line) were simultaneously
stained with 2 μM DCFH-DA and monoclonal PerCP-conjugated anti-CD3 antibody for 20 minutes, and ROS production was analyzed by FACS analysis.
Representative histogram of three independent experiments is shown. DCFH-DA, 2′, 7′-dichlorodihydrofluorescin diacetate; NAC, N-acetylcysteine; PBL,
peripheral blood lymphocytes; PerCP, peridinin chlorophyl protein; ROS, reactive oxygen species; SSc, systemic sclerosis.
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showed higher levels of Ha-Ras compared to control
cells. Moreover, treatment with NAC or DPI led to a
significant decrease in Ha-Ras expression, confirming
the activated state of SSc lymphocytes due to oxidative
stress (Figure 4C).
Modulation of ROS production by cytokines
To verify whether soluble mediators were involved in ROS
generation in T lymphocytes, we treated SSc and normal
T cells with IL-1 (10 ng/ml), IL-4 (15 ng/ml), IL-6 (5 ng/
ml), IL-13 (50 ng/ml), IFNα (0.5 ng/ml), TNFα (1 ng/ml),
TGFβ (1 ng/ml), and PDGF-BB (15 ng/ml) for 15 minutesbefore ROS analysis. IL-1, IL-6, TNFα, and TGFβ induced
a significant increase in ROS generation in normal T cells
(78 ± 5, 77 ± 7, 70 ± 5, 38 ± 5 respectively compared to
untreated cells 18 ± 10, P <0.05) (Figure 5A). In SSc T
cells instead ROS levels were not modified by incubation
with the same cytokines and growth factors (Figure 5B),
suggesting that SSc T cells were already maximally acti-
vated and were not responsive to external stimuli.
Biological effects of ROS in activated T cells
Under experimental conditions, functional analysis of T
lymphocytes requires in vitro stimulation that mimics as
closely as possible physiological in vivo activation of T cells
Figure 3 Role of NOX2 in ROS production by SSc T cells. (A) A representative gp91phox immunoblot of three independent experiments is
shown. T cells were isolated from healthy controls (N) and SSc patients (SSc) and then analyzed by immunoblotting with specific antibodies.
The lower panel shows the densitometric analysis from distinct experiments with five healthy controls and five SSc patients. Data are means ±
standard deviation (SD). *P <0.05 compared to normal T cells. (B) Real time-PCR for gp91phox expression in T cells was isolated from five healthy
controls and five SSc patients. Each patient and control was tested three times and the mean value used to calculate the mean of each group.
Data are means ± SD. *P <0.05 compared to normal T cells. (C) T cells isolated from five SSc patients were treated with DPI (20 μM, 1 hour),
stained with 20 μM DCFH-DA and subsequently analyzed in a plate reader fluorimeter. Each treatment was tested three times and the mean
value used to calculate the mean of each group. Data are means ± SD. *P <0.05 compared to untreated T cells (control). (D) ROS production in
SSc T lymphocytes transiently transfected with control siRNA (CTRL siRNA) or gp91phox targeted siRNA (gp91phox siRNA) for 72 hours (upper
panel). Data are means ± SD of three independent experiments with cells from three distinct patients. *P <0.05 compared to control siRNA.
Transfection efficiency was monitored by western blot (lower panel). DCFH-DA, 2′, 7′-dichlorodihydrofluorescin diacetate; NOX2, NADPH oxidase
2; ROS, reactive oxygen species; siRNA, small interfering RNA; SSc, systemic sclerosis.
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cytes with PMA and tested ROS production and ERK1/2
phosphorylation. Both normal and SSc cells showed over-
production of intracellular ROS (Figure S2A in Additional
file 3) and upregulation of pERK levels after PMA incuba-
tion (Figure S2B in Additional file 3).
PMA activation of CD4+ T cells was then assessed by
monitoring the expression of CD69, an early activation
marker on the surface of antigen-specific activated lympho-
cytes in vitro [32]. As shown in the upper panels of
Figure 6A and B, incubation of normal T cells with PMA
led to an increase of the activation rate on CD4+ cells (47%
increase compared to basal, P <0.05), that was partiallyreverted by treatment with DPI (30% increase compared to
basal). On the other hand, CD69 was upregulated in SSc T
cells compared to normal controls even in basal conditions
(15% increase compared to normal cells, Figure 6B), and
NADPH oxidase inhibition reverted the activated state of
SSc T lymphocytes (lower panels of Figure 6A and B).
To provide a more physiological mechanism of T cell
activation, we stimulated lymphocytes with magnetic
beads coated with anti-CD3 and anti-CD28 antibodies,
mimicking the binding of antigen-presenting cells to T
cells [33,34]. CD3-CD28 beads stimulation induced an in-
crease of ROS levels (Figure S3A in Additional file 4) and
CD69 expression in SSc and normal T cells (Figure 6C).
Figure 4 pERK1/2 implication in ROS production. (A) T lymphocytes from five SSc patients were incubated with PD98059 (50 μM, 2 hours) or left
untreated. After staining with 20 μM DCFH-DA, fluorescence was analyzed in a plate reader fluorimeter (left panel). Each treatment was tested three
times and the mean value used to calculate the mean of each group. Data are means ± standard deviation (SD). *P <0.05 compared to untreated T cells
(control). Representative histogram of ROS production by SSc T cells is shown in the right panel. Untreated (control, grey line) and PD98059 treated
cells (black line) were stained with 2 μM DCFH-DA and analyzed by FACS analysis. (B) Representative pERK1/2 immunoblot of three independent
experiments is shown (upper panel). T lymphocytes were isolated from five healthy controls and five SSc patients, treated with NAC (10 mM, 1 hour) or
DPI (20 μM, 1 hour), and then analyzed by immunoblotting with specific antibodies. The lower panel shows the densitometric analysis from distinct
experiments with five healthy controls and five SSc patients. Data are means ± SD. *P <0.05 compared to untreated normal T cells. **P < 0.05 compared
to untreated SSc T cells. (C) Representative Ha-Ras immunoblot of three independent experiments is shown (upper panel). T lymphocytes were isolated
from five healthy controls and five SSc patients, treated with NAC (10 mM, 1 hour) or DPI (20 μM, 1 hour), and then analyzed by immunoblotting with
specific antibodies. The lower panel shows the densitometric analysis from distinct experiments with five healthy controls and five SSc patients. Data
are means ± SD. *P <0.05 compared to untreated normal T cells. **P <0.05 compared to untreated SSc T cells. DCFH-DA, 2′, 7′-dichlorodihydrofluorescin
diacetate; DPI, diphenylene iodonium; NAC, N-acetylcysteine; ROS, reactive oxygen species; SSc, systemic sclerosis.
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Figure 5 Modulation of ROS production by cytokines. ROS production by T cells isolated from three healthy controls (A) and three SSc
patients (B) and treated with IL-1 (10 ng/ml), IL-4 (15 ng/ml), IL-6 (5 ng/ml), IL-13 (50 ng/ml), IFNα (0.5 ng/ml), TNFα (1 ng/ml), TGFβ (1 ng/ml),
and PDGF-BB (15 ng/ml) for 15 minutes. Cells were then stained with 20 μM DCFH-DA and analyzed in a plate reader fluorimeter. Data are
means ± standard deviation (SD) of three independent experiments with cells from three distinct subjects. *P <0.05 compared to untreated T cells.
DCFH-DA, 2′, 7′-dichlorodihydrofluorescin diacetate; IFNα, interferon alpha; IL, interleukin; PDGF-BB, platelet-derived growth factor beta; ROS,
reactive oxygen species; SSc, systemic sclerosis; Th, T helper; TGFβ, transforming growth factor beta; TNFα, tumor necrosis factor alpha.
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(Figure S3B in Additional file 4) as well as the levels of
the activation marker (Figure 6C and D).
To test the biological effects of ROS on T cells, we exam-
ined proliferation and cytokine production in normal and
SSc T cells. Activation of T lymphocytes with CD3/CD28
beads led to a significant increase of SSc cell proliferation
compared to normal cells, expressed as ratio between SSc
and normal cells (SSc/N) (Figure 7A). Treatment with
NADPH oxidase inhibitor significantly decreased the prolif-
eration rate (2 ± 0.2 vs. 1.15 ± 0.3, P <0.05), without influen-
cing cell viability (Figure S4 in Additional file 5). These
experiments were carried out in medium supplemented with
IL-2, in order to avoid cell death after 24 hours of culturing.
Finally we measured the intracellular cytokine production
in activated CD4+ lymphocytes in the presence or absence
of DPI. The number of IFNγ- and IL-4-producing CD4+ T
cells in SSc patients was significantly higher than in normal
controls (21.1% vs. 12.5% for IFN-γ, Figure 7B; 15% vs. 7.1%
for IL-4, Figure 7C; P <0.05). In normal cells the percentage
of IFNγ- and IL-4-producing CD4+ cells was not altered by
DPI treatment, while in SSc cells NADPH oxidase inhibition
led to an increase of the number of cytokine-producing cells
(25.1% vs. 21.1% for IFNγ, and 26.3% vs. 15 for IL-4,P <0.05), suggesting that IFNγ- and IL-4-production was in-
fluenced by oxidative stress (Figure 7B and C).
Discussion
Several lines of evidence suggest that immunological mech-
anisms play an important role in the pathogenesis of SSc. In
this respect, it is noteworthy that skin biopsies taken from
SSc patients in the early stages of the disease show perivas-
cular infiltrates consisting of activated tissue macrophages
and T cells before microscopic evidence of fibrosis [5,6].
T cells in skin lesions are predominantly CD4+ cells [6], dis-
play markers of activation [9], exhibit oligoclonal expansion
[35] and are predominantly type 2 helper T (Th2) [36].
Complex interactions between immune cells, fibroblasts
and endothelial cells occur via cytokines, chemokines and
growth factors and result in overproduction of ECM. How-
ever, a crucial role is also played by ROS as shown in previ-
ous studies [25,26] and in the present work, where we
demonstrated that PBLs from SSc patients produced high
levels of ROS compared to T cells from healthy controls,
even in absence of deliberate stimulation (Figure 2A).
Generation of superoxide and hydrogen peroxide has
been detected in T cells following stimulation of TCR
[12] and, in agreement with Staal et al. [37], the present
Figure 6 Modulation of T cell activation by ROS. (A) One representative flow cytometry analysis of CD69 expression is shown. PMA activated
normal T cells (upper panels) or SSc T cells (lower panels) were treated with DPI (20 μM, 1 hour). Plots represent live cells gated for CD4+ cells.
(B) Percentage of CD69+ cells in three healthy controls (upper panel) and three SSc patients (lower panel) are presented. Cells were treated as
in A. Data are means ± standard deviation (SD). *P <0.05 compared to untreated T cells. (C) One representative flow cytometry analysis of CD69
expression is shown. Normal T cells (upper panels) or SSc T cells (lower panels) were activated with CD3/CD28 magnetic beads and treated with
DPI (20 μM, 1 hour). Plots represent live cells gated for CD4+ cells. (D) Percentage of CD69+ cells in three healthy controls (upper panel) and
three SSc patients (lower panel) are presented. Cells were treated as in C. Data are means ± SD. *P <0.05 compared to untreated T cells. DPI,
diphenylene iodonium; PMA, phorbol myristate acetate; ROS, reactive oxygen species; SSc, systemic sclerosis.
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cyte proliferation mimicking growth factors and antigenic
stimulation.
In addition, another relevant finding that emerged
from our study is the reduced number of CD69+ SSc T
cells after exposure to DPI, suggesting that ROS are im-
plicated in the activation of CD4+ lymphocytes (lower
panels of Figure 6B and C). CD69 is a member of C-type
lectin like receptor family expressed in leukocytes fol-
lowing stimulation [38]. Although CD69 was considered
a marker of regulatory T (Treg) cells, recent studies
indicated that this molecule may be involved in their
immunosuppressive role. Radstake et al., interestingly,
demonstrated that although the expression of CD69 on
CD4+ SSc T cells was increased compared to controls,
its expression on SSc Treg was diminished and corre-
lated with a reduced suppressive function [39]. It re-
mains to be established whether ROS can modulate
CD69+ Treg function.
Furthermore, the present work showed that inhibition
of NADPH oxidase led to a further increase of INFγ pro-
duction in SSc T lymphocytes (Figure 7B). This findingwas recently confirmed by Yang et al. [40], demonstrating
that ROS scavenging in T lymphocytes from rheumatoid
arthritis patients increased INFγ production. Surprisingly,
our report also described an overproduction of IL-4 after
ROS inhibition in SSc T lymphocytes (Figure 7C). This
observation about the prevalence of cytokines, which
have a distinct functional role in the pathogenesis of
autoimmune diseases and fibrosis, is not new in SSc.
Some studies showed the predominance of Th1 cyto-
kines in SSc [41,42] while other reports demonstrated a
Th2 profile [36]. Valentini et al. reported evidence of
Th1 and Th2 activation in PBLs from SSc patients [43].
These conflicting data may be explained by heterogen-
eity within the groups studied, such as differences in the
subsets of patients enrolled in the studies, duration,
stage and activity of the disease, age and gender of pa-
tients and controls. Thus, further studies with well-
characterized patients are needed to better clarify the
link between oxidative stress and cytokine production
in SSc T cells.
Interestingly we showed that, as in SSc monocytes and
fibroblasts, the endogenous source of ROS is NOX2
Figure 7 Modulation of proliferation and cytokine production by ROS in activated T cells. (A) T cells from three healthy controls and three
SSc patients were activated with CD3/CD28 magnetic beads, treated with DPI (20 μM, 1 hour) and pulsed with BrdU for 6 hours. Proliferation
was measured with a colorimetric immunoassay in a plate reader fluorimeter. Data are means ± standard deviation (SD) of fold increase of SSc/N
proliferation ratio. *P <0.05. (B) One representative flow cytometry analysis of IFNγ-producing T cells is shown. Normal T cells (upper panels) or
SSc T cells (lower panels) were activated with CD3/CD28 magnetic beads and treated with DPI (20 μM, 1 hour). Plots represent live cells gated
for CD4+ cells. Percentage of IFNγ-producing T cells in three healthy controls and three SSc patients are presented (right panel). Data are
means ± SD. *P <0.05 compared to normal untreated T cells. **P <0.05 compared to SSc untreated T cells. (C) One representative flow cytometry
analysis of IL-4-producing T cells is shown. Normal T cells (upper panel) or SSc T cells (lower panel) were activated with CD3/CD28 magnetic
beads and treated with DPI (20 μM, 1 hour). Plots represent live cells gated for CD4+ cells. Percentage of IL-4-producing T cells in three healthy
controls and three SSc patients are presented (right panel). Data are means ± SD. *P <0.05 compared to normal untreated T cells. **P <0.05
compared to SSc untreated T cells. BrdU, bromodeoxyuridine; DPI, diphenylene iodonium; IFN, interferon; PMA, phorbol myristate acetate; ROS,
reactive oxygen species; SSc, systemic sclerosis.
Amico et al. Arthritis Research & Therapy  (2015) 17:68 Page 10 of 12which is overexpressed in SSc T cells both at mRNA and
protein level compared to normal cells (Figure 3A and B).
It is noteworthy that in SSc lymphocyte ROS generated by
NOX2 induce an autocrine loop, involving activated
ERK1/2 and overexpressed Ha-Ras, which maintains high
levels of the oxidase and activation of the lymphocytes.
This ROS-mediated loop characterizes all SSc cell linesstudied so far [25,26] and thus should be considered a
priority target in the development of novel anti-fibrotic
therapies.
Conclusions
Our work provided evidence that T cells isolated from SSc
patients contribute to the oxidative stress of systemic
Amico et al. Arthritis Research & Therapy  (2015) 17:68 Page 11 of 12sclerosis, and showed that ROS were generated by
NADPH oxidase and involved in the activation of SSc T
cells. These findings confirm once more the pathogen-
etic role of oxidative stress in SSc and indicate that
NADPH oxidase may represent a potential target to be
considered for the treatment of systemic sclerosis.Additional files
Additional file 1: Table S1. Clinical characteristics of SSc cohort.
Additional file 2: Figure S1. (A) ROS production by CD4+ PBL from
one SSc patient, simultaneously stained with 2 μM DCFH-DA and
monoclonal antibody anti-CD4 PE for 20 minutes, was analyzed by
FACS analysis. (B) ROS production by CD8+ PBL from one SSc patient,
simultaneously stained with 2 μM DCFH-DA and monoclonal antibody
anti-CD8 PE for 20 minutes, was analyzed by FACS analysis.
Additional file 3: Figure S2. (A) Representative histogram of ROS
production by PMA (100 ng/ml, 4 hours) activated normal T cells (left
panel) or by SSc T cells (right panel). Untreated (grey line) and PMA
activated cells (black line) were stained with 2 μM DCFH-DA and analyzed
by FACS analysis. (B) Immunoblot analysis of pERK1/2 and ERK2 in cells
treated as in (A).
Additional file 4: Figure S3. (A) Representative histogram of ROS
production by normal T cells (green line) or SSc T cells (black line)
activated with CD3/CD28 magnetic beads. Cells were stained with 2 μM
DCFH-DA and analyzed by FACS analysis. (B) Representative histogram
of ROS production by SSc T cells activated with CD3/CD28 magnetic
beads in the presence (green line) or absence of DPI (grey line). Cells
were stained with 2 μM DCFH-DA and analyzed by FACS analysis.
Additional file 5: Figure S4. Normal and SSc T cells activated with
CD3/CD28 magnetic beads were treated with DPI (20 μM, 2 hours)
and incubated with 7-AAd for 20 minutes and analyzed by FACS. One
representative experiment of three is shown.Abbreviations
7-AAD: 7-aminoactinomycin D; BrdU: bromodeoxyuridine; conA: concanavalin
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